[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Immorna Biotherapeutics, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100576117",false,"NCT06781125","One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors","A Phase I\u002FII Clinical Trial to Evaluate the Safety and Tolerability of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody IV Infusion in Patients With Malignant Solid Tumors","Inclusion Criteria:\n\n1. Male or female patients, aged 18 to 75 years;\n2. patients with malignant solid tumors confirmed by pathology and\u002For cytology who have progressed or are intolerant to standard treatment (except best supportive care); Including patients who have received prior anti-PD-1 antibody therapy; patients who have been approved as eligible for Toripalimab:\n3. General condition score ECOG 0 \\~ 1;\n4. Expected survival of more than 3 months;\n\nExclusion Criteria:\n\n1. Known or suspected allergy to the ingredients of the study drug or its analogues; allergic history to another monoclonal antibody;\n2. patients who have previously received IL-12 therapy (alone or as part of a treatment regimen), except those who have participated in tolerance to a single intratumoral injection;\n3. patients who have previously received treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or have received treatment directed at another stimulatory or coinhibitory T-cell receptor (e.g., CTLA-4, OX-40, CD137), and discontinued treatment due to Grade 3 or higher immune-related adverse events (irAEs);","ALL","18 Years","75 Years",{"count":19,"type":20},72,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","This is an open-label, dose-escalation and dose-expansion Phase I \u002FII clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with malignant solid tumors.",[27],"Malignant Solid Tumors","NOT_YET_RECRUITING","2026-03-20",{"date":31,"type":32},"2026-03-24","ACTUAL",{"date":34,"type":20},"2026-03-18",{"date":36,"type":20},"2028-06-30",{"name":38,"class":39},"Immorna Biotherapeutics, Inc.","INDUSTRY",""]